Medicinal charcoal as a pharmaceutical product
Activated charcoal is listed in the major pharmacopoeias as a medicinal product — used for the treatment of diarrhoea, flatulence, and in emergency treatment of certain poisonings. It is one of the oldest and most continuously used pharmaceutical substances, appearing in the Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), and United States Pharmacopeia (USP).
What pharmacopoeial grade means
A pharmacopoeial grade designation (USP, BP, IP) means that the activated charcoal meets the specifications defined in the relevant pharmacopoeia for identity, purity, loss on drying, methylene blue adsorption, and absence of harmful impurities including heavy metals and arsenic.
The pharmacopoeia defines test methods and acceptance limits — the manufacturer must test every batch and certify compliance. This is fundamentally different from food-grade or industrial-grade carbon, which may meet different, less stringent specifications.
Key pharmacopoeial tests
- Methylene blue adsorption — the primary activity test; a minimum MB value confirms adequate adsorption capacity
- Arsenic limit — critical for human use; pharmacopoeial limits are extremely tight (typically < 2 ppm)
- Heavy metals — lead, mercury, cadmium limits defined and tested
- Loss on drying — moisture content specification
- pH of aqueous suspension — important for tolerance in oral administration
Rajindra’s IP/BP/USP grade activated charcoal is produced specifically for medicinal tablet and suspension manufacturing. Every batch ships with a full Certificate of Analysis against the relevant pharmacopoeial specifications.
Tablet formulation requirements
For activated charcoal tablet manufacturing, the carbon must be compatible with tablet excipients, have consistent particle size, and be low in moisture to ensure stable tablet production. Powdered charcoal for tablets is typically in the 100–200 mesh range.